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Abstract
AIM: To report the clinical impact of adrenal endoscop-
ic ultrasound fine-needle aspiration (EUS-FNA) in the 
evaluation of patients with adrenal gland enlargement 
or mass.
METHODS: In a retrospective single-center case-
series, patients undergoing EUS-FNA of either adrenal 
gland from 1997-2011 in our tertiary care center were 
included. Medical records were reviewed and results of 
EUS, cytology, adrenal size change on follow-up imag-
ing ≥ 6 mo after EUS and any repeat EUS or surgery 
were abstracted. A lesion was considered benign if: (1) 
EUS-FNA cytology was benign and the lesion remained 
< 1 cm from its original size on follow-up computed 
tomography (CT), magnetic resonance imaging or re-
peat EUS ≥ 6 mo after EUS-FNA; or (2) subsequent 
adrenalectomy and surgical pathology was benign. 
RESULTS: Ninety-four patients had left (n  = 90) 
and/or right (n  = 5) adrenal EUS-FNA without adverse 
events. EUS indications included: cancer staging or sus-
pected recurrence (n  = 31), pancreatic (n  = 20), medi-
astinal (n  = 10), adrenal (n  = 7), lung (n  = 7) mass or 
other indication (n  = 19). Diagnoses after adrenal EUS-
FNA included metastatic lung (n  = 10), esophageal 
(n= 5), colon (n  = 2), or other cancer (n  = 8); benign 
primary adrenal mass or benign tissue (n  = 60); or was 
non-diagnostic (n  = 9). Available follow-up confirmed a 
benign lesion in 5/9 non-diagnostic aspirates and 32/60 
benign aspirates. Four of the 60 benign aspirates were 
later confirmed as malignant by repeat biopsy, follow-
up CT, or adrenalectomy. Adrenal EUS-FNA diagnosed 
metastatic cancer in 24, and ruled out metastasis in 10 
patients. For the diagnosis of malignancy, EUS-FNA of 
either adrenal had sensitivity, specificity, positive predic-
tive value and negative predictive value of 86%, 97%, 
96% and 89%, respectively.
CONCLUSION: Adrenal gland EUS-FNA is safe, mini-
mally invasive and a sensitive technique with significant 
impact in the management of adrenal gland mass or 
enlargement.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Studies evaluating endoscopic ultrasound 
fine-needle aspiration (EUS-FNA) of the adrenal gland 
generally include patients with underlying malignancy 
only and most lack follow-up for benign lesions. We 
report the clinical utility of adrenal gland EUS-FNA in a 
retrospective study that included 94 patients who un-
derwent EUS-FNA of either adrenal for various indica-
tions and provide follow-up information for those with 
benign EUS-FNA cytology results. For the diagnosis of 
malignancy, EUS-FNA of either adrenal had sensitiv-
ity, specificity, positive predictive value and negative 
predictive value of 86%, 97%, 96% and 89%, without 
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serious adverse events. 
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INTRODUCTION
The development of  modern imaging techniques such 
as ultrasonography, computed tomography (CT), and 
magnetic resonance imaging (MRI), has led to increased 
detection of  adrenal masses, which are found in up to 
5% of  patients undergoing CT of  the abdomen[1]. The 
incidence of  an adrenal incidentaloma (detection of  an 
otherwise unsuspected adrenal mass on imaging), ranges 
from 0.2%-7% as reported in autopsy series[2]. Most of  
these incidentally found lesions are non-functioning ad-
enomas, but 2% are metastatic lesions[3].
About 75% of  adrenal masses identified during stag-
ing of  patients with cancer are metastatic lesions which 
are most commonly metastases from lung, breast, stom-
ach and kidney, as well as, melanomas and lymphomas[2]. 
The sensitivity and specificity of  imaging techniques are 
currently insufficient to differentiate benign from ma-
lignant masses, therefore, patients with a high index of  
suspicion for malignancy are often referred for percuta-
neous biopsy[4].
Image-guided fine needle aspiration (FNA), using ei-
ther ultrasound (US) or CT and percutaneous approach, 
have traditionally been used for sampling of  the adrenal 
glands[5,6]. However, this technique yields non-diagnostic 
samples in up to 14% of  patients and is associated with 
adverse events in 0.4%-12%[7,8].
Endoscopic ultrasound guided-fine needle aspiration 
(EUS-FNA) of  either adrenal offers a minimally invasive 
and accurate method for sampling the adrenals with a 
low risk profile[3,9-12]. However, studies to date have most-
ly included patients with underlying malignancy and the 
great majority lack follow-up imaging for benign lesions 
or include follow-up for few patients[4,12,13]. This study 
reports the utility of  EUS-FNA in patients with known 
adrenal gland enlargement or a mass, and the impact of  
the EUS-FNA cytology result on patient care, final diag-
nosis and adverse events from the procedure.
MATERIALS AND METHODS
This retrospective single-center case series was approved 
by the institutional Review Boards at the Indiana Univer-
sity Health School of  Medicine in Indianapolis Indiana. 
Cytology and EUS databases between October 1997 and 
December 2011 were reviewed to identify all patients 
who underwent EUS-FNA of  either adrenal gland. The 
original 38 patients were previously described in a 2007 
publication from our hospital[3]. Medical records were 
reviewed and results of  imaging (CT and MRI) prior to 
the procedure, EUS indications and findings, cytologi-
cal investigations and complications were recorded. In 
addition, follow-up clinical information and any repeat 
adrenal imaging or surgery of  the adrenal gland was ab-
stracted. For patients without available follow-up on our 
medical records, referring physicians were contacted by 
phone to obtain this information. Through institutional 
protocol, all patients were called within 48 h after EUS 
to assess for any short-term adverse events not already 
identified. Adverse events were defined as: systolic blood 
pressure less than 80 mmHg at any time during the pro-
cedure, hypoxemia (oxygen saturation less than 85% on 
room air or on baseline oxygen supplementation), brady-
cardia (heart rate less than 50 beats per minute), bleeding 
recognized during EUS or subsequent imaging studies 
with hemoglobin drop of  ≥ 2 g/dL from baseline, need 
for blood transfusion within 48 h of  the procedure, 
pneumothorax, abdominal pain, hypertensive urgency 
and, requirement for hospitalization. 
EUS
After obtaining written informed consent, patients re-
ceived conscious sedation using various combinations of  
intravenous midazolam, meperidine, fentanyl or propo-
fol under appropriate cardiorespiratory monitoring. All 
procedures were done by or under the supervision of  
one of  seven attending endoscopists. Radial endosonog-
raphy (Olympus GFUM-20, GFUM-130, GFUM-160 or 
GFUE160-AL5; Olympus America, Center Valley, PA; 
United States), was performed initially in some patients. 
Linear EUS (Olympus GF-UC30P, Olympus GF-UC140P, 
or Pentax 32-UA or 36-UX; Pentax Medical, Montvale, 
NJ; United States), was performed in all patients. 
The left adrenal gland was visualized by one of  2 
methods. First, the descending aorta was followed to the 
celiac axis; once this was seen, the left adrenal gland was 
visualized after a slight clockwise rotation and withdraw-
al movement. Alternatively, the splenic vein posterior 
to the body of  the pancreas was identified by transgas-
tric imaging; clockwise rotation and withdrawal of  the 
echo endoscope following the splenic vein laterally then 
permitted the identification of  the left adrenal gland 
superior to the upper pole of  the left kidney. Transduo-
denal imaging of  the right adrenal gland with EUS was 
performed with the echoendoscope in the long position 
along the greater curvature of  the stomach. The inferior 
vena cava or the right kidney was then visualized, and 
then right adrenal gland was uniformly present between 
the superior pole of  the right kidney, the liver and the 
inferior vena cava. EUS exams for patients in this study 
attempted to image a known or suspected adrenal mass 
or enlargement and did not routinely attempt to visualize 
both adrenal glands
The size of  the adrenal gland for study purposes was 
the maximal cross-sectional diameter of  the gland. An 
adrenal gland mass was considered to be a focal enlarge-
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ment of  the gland with a notable discrete mass, whereas, 
adrenal gland enlargement was considered when the 
gland was diffusively increased size without a visible dis-
crete mass. 
EUS-FNA was performed using a 19, 22 or 25 gauge, 
8 cm needle (Cook-Medical, Winston-Salem, NC; United 
States or Boston Scientific, Natick, MA; United States). 
Minimal clotting parameters required to perform EUS-
FNA were a platelet count of  ≥ 50000 and INR ≤ 1.5. 
Color Doppler imaging was used to ensure the absence 
of  intervening vascular structures along the anticipated 
needle path. After needle puncture of  the adrenal gland, 
the stylet was removed. At the discretion of  the endo-
sonographer, suction was applied to the proximal end of  
the needle with a vacuum containing syringe. If  excess 
blood was present in the initial specimen, subsequent 
passes with the same needle were attempted without 
suction. There was no maximum number of  biopsy at-
tempts allowed. Biopsy attempts were performed at the 
discretion of  the endosonography until considered that 
useful clinical information was provided, or that further 
attempts would be futile. According to our routine en-
doscopy unit protocol, patients were monitored in the 
recovery area after EUS imaging for at least 60 min be-
fore discharge. No additional monitoring was performed 
after adrenal biopsy. 
cytological examination
Aspirates were expressed and smeared onto 2 glass slides. 
One slide was air-dried and stained with a modified Gi-
emsa stain for on-site interpretation, while the other slide 
was alcohol-fixed and stained using the Papanicolaou 
method. A cytotechnologist and/or cytopathologist, not 
blinded to the patient’s clinical history, were available on-
site for real-time preliminary interpretation for all proce-
dures; this added an additional 2-3 min to the procedure 
for each FNA pass. Additional aspirates were submitted 
for immunocytochemical analysis at the discretion of  the 
cytopathologist to confirm metastatic malignancy when 
required.
Cytology reports were characterized as “diagnostic 
for malignancy”, “benign adrenal tissue”, or “non-diag-
nostic”. The following were considered to be cytologic 
features of  benign adrenocortical tissue: clusters of  
cells with a foamy cytoplasm and smoothly contoured, 
round to oval nuclei, all within a vacuolated or foamy 
background with occasional single cells[13]. Diagnostic 
cytology specimens were considered to include any of  
the following: benign-appearing cytologic features of  the 
adrenal gland, primary adrenal neoplastic tissue, or meta-
static malignant cells. Non-diagnostic cytology speci-
mens had none of  these three features but did show any 
of  the following: amorphous debris, blood, or gastric 
contaminant.  
Study definitions
The final diagnosis was made on the basis of  the surgical 
pathology if  resection was performed, unequivocal cytol-
ogy from EUS-FNA, clinical follow-up, or the stability 
of  lesion size as assessed by subsequent imaging studies. 
An adrenal lesion was considered stable (and therefore 
benign) if  size was within 1 cm by follow-up imaging (CT 
or MRI) obtained at least 6 mo after EUS-FNA[14]. EUS-
FNA of  either adrenal gland was considered to have 
had an impact on patient care if  the cytology resulted in 
either: (1) benign cytology which excluded adrenal metas-
tasis and permitted resection of  the primary tumor; or (2) 
initial diagnosis of  malignancy, distant metastasis, tumor 
recurrence or primary adrenal neoplasm. 
Statistical analysis
For analysis, continuous variables were described as 
means and standard deviations, and dichotomous vari-
ables were expressed as simple proportions, with or 
without 95%CI. Student’s t test and Fisher’s exact tests 
were used to test for differences in comparisons between 
continuous and dichotomous variables, respectively. 
For calculating test characteristics of  EUS-FNA for the 
diagnosis of  malignancy, only aspirates interpreted as di-
agnostic for malignancy on cytological examination were 
considered as true positives. Patients with subsequent 
adrenalectomy, percutaneous adrenal biopsies or follow-
up abdominal imaging of  the adrenal at least 6 mo after 
EUS were utilized to calculate the test characteristics of  
EUS-FNA for the diagnosis of  non-malignant (benign 
or non-diagnostic) specimens. 95% confidence intervals 
were calculated when appropriate. A p value less than 0.05 
was considered statistically significant.
RESULTS
94 consecutive patients (52% men; median age: 66 years, 
range 32-86) underwent 95 attempted EUS-FNA of  the 
left (n = 90) and/or right (n = 5) adrenal gland during 
the study period. There were no adverse events related to 
these procedures. Patient characteristics and EUS find-
ings by results of  diagnostic and non-diagnostic biopsies 
are summarized in Table 1. Patients with diagnostic ma-
lignant biopsies had smaller lesions than those with di-
agnostic benign lesions (p = 0.027) otherwise the clinical 
and EUS features of  the two groups were similar. Indica-
tions for EUS in all 94 patients are summarized in Table 
2. Known adrenal gland enlargement, fullness or mass 
according to previous imaging was present in 55 (59%). 
A previous diagnosis of  cancer was present in 40 patients 
(42%) (Table 3). 
Prior attempt with percutaneous CT-guided approach 
for adrenal biopsy was performed and unsuccessful in 3 
patients, two of  them subsequently had a diagnostic ad-
renal EUS-FNA (1 malignant, 1 benign); the third patient 
had a non-diagnostic EUS-FNA of  the adrenal gland. 
EUS findings and cytology
The mean maximal diameters for the right and left adre-
nal masses were 3.5 ± 0.88 cm and 2.72 ± 1.36 cm, respec-
tively. EUS identified an adrenal mass in the 5 (100%) pa-
tients who underwent right adrenal EUS-FNA and in 75/90 
(83%) who underwent left EUS-FNA. The left 15 adrenals 
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without mass demonstrated only diffuse enlargement (one 
patient had bilateral adrenal EUS-FNA) (Table 1). 
Nine aspirations were non-diagnostic (9.5%). Four 
of  these, had a previous diagnosis of  cancer and 6 had 
an identified adrenal mass during EUS with a mean mass 
diameter of  2.4 ± 1.2 cm. Non-diagnostic aspirations 
occurred mostly before 2004, however the frequency be-
fore and after 2004 was not different (p = 0.14), and this 
was considered to be related to operator’s learning curve 
(Table 4).
Diagnostic cytology was obtained in 86 biopsies after 
a mean of  3.2 ± 1.4 needle passes. There was no statisti-
cal significance between the number of  needle passes 
for diagnostic biopsies and non-diagnostic biopsies (p 
= 0.98). All nondiagnostic biopsies were from the left 
adrenal gland; all right adrenal biopsies were diagnostic. 
Ninety-one fine-needle aspirations were performed with 
a 22G needle and included all the specimens that yielded 
a non-diagnostic sample. Only 3 and 1 biopsies on these 
series were obtained with a 25 G and a 19 G needle, re-
spectively.
Adrenal gland FNA was malignant in 26% (n = 25) 
and benign in 64% (n = 60). Details about adrenal gland 
EUS-FNA cytology results are summarized in Table 5.
clinical follow-up
Follow-up was available for 36/60 (60%) patients with 
benign adrenal cytology. The remaining 24 patients either 
were: lost to follow-up (n = 4), did not get repeat adrenal 
gland imaging (n = 5) or died (n = 15). The 15 patients 
died a mean of  28 ± 36 mo after EUS without follow 
imaging.
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  Characteristics Diagnostic
(n  = 85)
Non-diagnostic
(n  = 9)
P  value
Benign
(n  = 60)
Malignant
(n  = 25)
  Age (mean ± SD) 67 ± 11 63 ± 14 0.161
66 ± 12 66 ± 11 0.992
  Race 
     White 57 (95) 25 (100) 7 (78)
     African American 3 (5) 0 (0) 2 (22)
     Hispanic 0 (0) 0 (0) 0 (0)
  Gender ≥ 0.993
     Male 26 (27) 19 (20) 5 (5)
     Female 34 (36) 6 (7) 4 (5)
  Adrenal biopsied ≥ 0.994
     Left 58 (61) 23 (24) 9 (10)
     Right 2 (2) 3 (3) 0 (0)
  EUS image of adrenal 
     Mass 49 (52) 25 (26) 6 (6) 0.145
     Diffuse 
     enlargement
11 (12) 1 (1) 3 (3) 0.096
  Size by EUS, cm
     Mean ± SD 3.4 ± 1.6 2.6 ± 1.2   0.0277
     Mean ± SD 2.8 ± 1.4 2.4 ± 1.2 0.418
     Range 0.7-5.2 1.3-7.0 1.0-4.0
  Echogenicity
     Hypoechoic 40 (42) 22 (24) 4 (4)
     Hyperechoic 1 (1) 0 (0) 1 (1) 0.149
     Not reported or 
     unavailable
19 (20) 4 (4) 4 (4)
  Number of FNA passes
     Mean ± SD 3.0 ± 1.7 3.0 ± 1.3 3.1 ± 1.5 0.461
Table 1  Patients characteristics and endoscopic ultrasound 
findings  n  (%)
1Mean age diagnostic vs non-diagnostic; 2Diagnostic vs non-diagnostic 
cytology result based on gender; 3Adrenal Gland FNA side and Diagnostic 
vs non-diagnostic cytology result; 4Presence or absence of an adrenal mass 
and diagnostic vs non-diagnostic cytology result; 5Presence of absence of 
an adrenal mass and benign vs malignant FNA cytology; 6Median size by 
EUS (cm) and malignant vs benign FNA cytology; 7Median size by EUS 
(cm) and Diagnostic vs non-diagnostic cytology; 8Adrenal Echogenicity on 
EUS and Diagnostic vs non-diagnostic cytology; 9Number of FNA passes; 
and Diagnostic vs non-diagnostic FNA; 10Mean age benign vs malignant. 
EUS: Endoscopic ultrasound; FNA: Fine-needle aspiration.
  Indication for EUS n  (%)
  Cancer staging1   26 (27)
  Suspected cancer recurrence2   5 (6)
  Abnormal CT/PET-CT or MRI
     Pancreatic mass   20 (21)
     Mediastinal mass   10 (11)
     Lung mass   7 (7)
     Adrenal mass   7(7)
     Gastric mass   2 (2)
     Liver mass   3 (3)
     Kidney mass   1 (1)
     Retroperitoneal mass   1 (1)
  Other3   12 (13)
  Total of patients                94
Table 2  Indications for endoscopic ultrasound 
1Esophageal cancer (n = 3), gastric cancer (n = 2), breast (n = 1), jejunal 
adenocarcinoma (n = 1), renal cell cancer (n = 2), cholangiocarcinoma (n = 
1), lung cancer (n = 16); 2Suspected recurrence of oral cancer (n = 1), breast 
cancer (n = 1), hepatoma (n = 1), lung adenocarcinoma (n = 1), esophageal 
adenocarcinoma (n = 1); 3Chronic pancreatitis (n = 3), abnormal upper 
endoscopy (n = 3), common bile duct stricture (n = 2), celiac nerve block (n 
= 1), suspected metastatic disease on imaging (n = 1), Barrett’s esophagus 
with high grade dysplasia (n = 1), ectatic pancreatic duct (n = 1). EUS: En-
doscopic ultrasound; PET: Positron emission tomography; CT: Computed 
tomography.
  Previous diagnosis of 
  cancer (n  = 40)
Benign 
cytology on 
EUS-FNA 
(n  = 21)
Malignant 
cytology on 
EUS-FNA 
(n  = 15)
Non-diagnostic 
cytology on 
EUS-FNA 
(n  = 4)
  Penile cancer 0 1 0
  Oral SCC 0 1 0
  Lung cancer          15 3 1
  Renal cell carcinoma 0 2 1
  Esophageal ADC 1 3 0
  Breast cancer 1 1 0
  Gastric ADC 1 1 0
  Hepatocellular carcinoma 0 1 0
  Pulmonary carcinoid 0 0 1
  Colon ADC 0 1 1
  SCC of the duodenum 1 0 0
  Basal cell cancer of the skin 1 0 0
  Bladder cancer 1 0 0
  Melanoma 0 1 0
Table 3  Previous diagnosis of cancer in patients undergoing 
endoscopic ultrasound guided fine-needle aspiration 
EUS-FNA: Endoscopic ultrasound guided fine-needle aspiration; SCC: 
Squamous cell carcinoma; ADC: Adenocarcinoma.
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Available follow-up for 5/9 (55%) patients with non-
diagnostic biopsies, demonstrated a stable adrenal lesion 
on repeat CT or MRI; the remaining four died before 
follow-up imaging (Figure 1). Median follow-up for be-
nign and non-diagnostic biopsies was 24 mo (range 4-96) 
and 12 mo (range 7-36), respectively. 
In 36 patients with benign adrenal cytology, available 
follow-up from imaging in 28 showed a stable adrenal 
lesion on CT (n = 27) or repeat EUS (n = 1). Five ad-
ditional patients underwent adrenalectomy and without 
repeat imaging in 4. In these five, surgical pathology was 
benign in 4 and demonstrated an adrenocortical carcino-
ma in 1 (Table 6). For the remaining three, 2 had subse-
quent CT-guided adrenal biopsy showing metastatic non-
small cell lung cancer in one (4 mo after EUS) and large 
cell neuroendocrine tumor in another (EUS-FNA biopsy 
of  the pancreas had previously showed neuroendocrine 
tumor). Finally, one patient had follow-up CT 6 mo after 
EUS that demonstrated a new contralateral adrenal mass 
with findings of  metastatic disease to the adrenals (Table 6). 
In one additional patient with history of  melanoma, 
CT scan for surveillance revealed a left adrenal mass. 
EUS-FNA of  the mass was malignant, however, adrenal-
ectomy 1 mo later showed benign pathology.
clinical impact of EUS-FNA
For the diagnosis of  malignancy EUS-FNA of  the adre-
nal gland had a sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV) of  86% 
(95%CI: 68%-95%), 97% (95%CI: 83%-100%), 96% 
(95%CI: 79%-100%) and 89% (95%CI: 74%-96%), re-
spectively. The sensitivity, specificity, positive predictive 
value and negative predictive value of  adrenal gland EUS-
FNA for benign lesions was 97% (95%CI: 83%-100%), 
86% (95%CI: 68%-95%), 89% (95%CI: 74%-96%) and 
96% (95%CI: 79%-100%), respectively. 
The diagnostic accuracy of  adrenal gland EUS-FNA 
was 92% for both benign and malignant lesions. 
Only 2 patients died within 6 mo of  the procedure. 
If  these two were hypothetically included as false-
negative biopsies, test characteristics for the diagnosis of  
malignancy would change to: sensitivity 80%, specificity 
97%, positive predictive value 96% and negative predic-
tive value to 84%. 
In patients with benign adrenal gland cytology, EUS-
FNA ruled out adrenal metastasis in 10 patients with 
underlying malignancy available follow-up (adrenalec-
tomy or follow-up imaging). EUS-FNA of  the adrenal 
gland made the initial diagnosis of  stage Ⅳ cancer in 18 
patients (lung cancer in 10, undifferentiated carcinoma 
in 1 and, esophageal in 4, colon in 2 and pancreatic ad-
enocarcinoma in 1), and initial diagnosis of  cancer recur-
rence in 6 patients (RCC in 2, oral SCC in 1, HCC in 1, 
esophageal cancer in 1 and breast cancer in 1). 
Benign cytology and exclusion of  metastases in 
10/36 patients with malignancy or a precancerous le-
sion (non-small cell cancer in 7, gastrointestinal stromal 
tumor in 1, esophageal adenocarcinoma in 1, and gastric 
adenocarcinoma in 1) permitted subsequent surgery. 
EUS-FNA of  the adrenal gland confirmed an initial 
diagnosis of  unsuspected pheochromocytoma in one 
patient. Finally, unnecessary surgery was avoided in 18 
patients with metastatic disease and 6 patients with can-
cer recurrence. 
DISCUSSION
Adrenal gland adenomas are discovered in 5% of  ab-
dominal CT exams, in 2%-9% of  autopsy studies and 
up to 4%-7% of  patients with potentially resectable lung 
cancer, therefore accurate characterization of  these le-
sions in cancer patients is essential[12,15]. Unfortunately, 
sensitivity and specificity of  imaging techniques are cur-
rently insufficient to differentiate benign from malignant 
masses and, false-negative and false-positive rates by CT 
scan both average 10%[4]. 
Distinguishing a metastatic lesion from a primary 
adrenal tumor is aided by the knowledge of  past cancer 
type and contrast-enhanced CT of  the chest, abdomen 
and pelvis. Fluorodeoxyglucose (FDG)-positron emis-
sion tomography (PET)/CT is increasingly used in re-
staging protocols for FDG-avid malignant tumors and 
can aid to document other extra-adrenal metastatic le-
sions[16]. According to the AACE/AAES (American As-
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  Timing of 
  EUS-FNA
Diagnostic 
EUS-FNA 
Non diagnostic 
EUS-FNA 
Total 
EUS-FNA
  Before 01/2004 31 (33)   6 (7) 37
  After 2004 54 (57) 3 (3) 57
  Total 85 (90)   9 (10) 94
Table 4  Timing of diagnostic and non-diagnostic biopsies  n (%)
Non diagnostic EUS-FNA before 2004 vs after 2004 (P  = NS). EUS-FNA: 
Endoscopic ultrasound guided fine-needle aspiration.
  EUS-FNA cytologic diagnosis n
  Malignant EUS-FNA cytology (26%, n = 25) 
     Metastatic lung cancer 10
     Metastatic esophageal adenocarcinoma   5
     Metastatic colon adenocarcinoma   2
     Metastatic renal cell carcinoma   2
     Metastatic breast adenocarcinoma   1
     Metastatic pancreatic adenocarcinoma   1
     Metastatic melanoma   1
     Metastatic oral squamous cell carcinoma   1
     Metastatic hepatocellular carcinoma   1
     Undifferentiated carcinoma   1
  Benign EUS-FNA cytology (64%, n = 60)
     Benign adrenal tissue 57
     Aldosteronoma   1
     Paraganglioma   1
    Pheochromocytoma1   1
Table 5  Cytology results from adrenal gland endoscopic ul-
trasound guided fine-needle aspiration 
1Previously negative normal plasma catecholamines and, 24-h urine 
normetanephrines, vanillylmandelic acid and metanephrines. EUS-FNA: 
Endoscopic ultrasound guided fine-needle aspiration.
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sociation of  Clinical Endocrinologists and American As-
sociation of  Endocrine Surgeons) guidelines, CT-guided 
FNA of  an adrenal lesion can be performed to confirm 
metastatic disease if  a definitive diagnosis is needed for 
oncologic treatment planning[16].
In our series, the sensitivity, specificity, PPV and 
NPV of  adrenal gland EUS-FNA for the diagnosis of  
malignancy was of  86%, 97%, 96% and 89%, respective-
ly. These results are similar to other series which report 
adrenal gland EUS-FNA sensitivity and negative predic-
tive value rates ranging from 86%-100% and 70%-100%, 
respectively yet most of  these studies have only included 
patients with underlying lung cancer [6,13]. 
With the widespread availability of  CT and therefore 
percutaneous CT-guided fine-needle aspiration of  the 
adrenals, the use of  EUS-FNA to obtain adrenal gland 
biopsy could be questioned. While percutaneous CT-
guided adrenal gland EUS-FNA of  lesions of  2.8-5 cm 
in size, has been reported to be reliable and predict a 
benign course on long term follow up in patients with 
a benign cytology result[17], the reported rate of  com-
plications from percutaneous CT-guided adrenal gland 
EUS-FNA ranges from 0%-12% with an overall rate of  
5.3%[7,15]. The most frequent adverse events related to 
percutaneous adrenal biopsies include hemorrhage and 
pneumothorax. Less common adverse events are pain, 
pancreatitis, and rarely needle-tract seeding. In our study 
we identified no short term (< 48 h) adverse events in 
any patient and no adverse events in those with available 
long term follow-up. In the current series, we performed 
diagnostic left adrenal biopsies in 2 of  3 patients in 
whom percutaneous approach of  the left adrenal gland 
had been previously attempted unsuccessfully. These 
findings have been reported by others and emphasize 
that EUS-FNA may be utilized as a rescue procedure for 
those in whom percutaneous biopsies are contraindicat-
ed or unsuccessful[9]. Taken together, EUS-FNA appears 
to be a safe procedure and an acceptable alternative to 
percutaneous sampling of  the adrenal glands.
About 5% of  all incidentally discovered adrenal le-
sions are pheochromocytomas, and 25% of  all pheo-
chromocytomas are discovered incidentally. Typical 
features of  pheochromocytomas include paroxysmal 
hypertension, headaches, sweating and palpitations; but, 
patients may not present with classical symptoms and 
up to 8% may be asymptomatic[18]. Sood et al[18] reported 
3 cases of  patients with catecholamine secreting tumors 
who underwent CT-guided percutaneous mass biopsy, 
including one with a pheochromocytoma and did not 
experience any adverse events related to the biopsy. In 
our series, one patient was unexpectedly diagnosed with 
pheochromocytoma by EUS-FNA and did not experi-
ence any adverse events from the procedure.
EUS shows a normal or minimally enlarged left adre-
nal gland in 98% of  patients compared with only a 69% 
by transabdominal ultrasound[19]. A normal or minimally 
enlarged right adrenal gland, however, is seen in only 
30% of  patients on EUS, whereas transabdominal ultra-
sound permits detection in nearly all patients. Therefore, 
left adrenal EUS-FNA is attempted more often than 
right adrenal biopsies[19]. Recently, Uemura reported a 
rate of  visualization of  the right adrenal gland of  87.3% 
(n = 150) on EUS[13]. To date, there have been only a few 
reports of  successful right adrenal gland EUS-FNA, but 
no large case-series[9-12,20]. The utility of  EUS-FNA of  
right adrenal masses requires further clarification.
In our case series, the median adrenal gland diameter 
was higher in patients with diagnostic benign biopsies 
compared to malignant FNA specimens. This is in con-
trast with the results reported by Eloubeidi et al[12] who 
found larger masses in patients with malignancy (3.1 
cm) compared to those with benign lesions (2.3 cm). A 
potential reason for this difference is that our group has 
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94 patients
Benign (n  = 60) Non-diagnostic 
(n  = 9)
Malignant 
(n  = 25)
Follow-up not
available (n  = 24)
Benign by 
clinical follow-up
(n  = 5)
Malignant by 
clinical follow-up
(n  = 0)
Follow-up not 
available (n  = 4)
Benign by 
clinical follow-up
(n  = 32)
Malignant by 
clinical follow-up
(n  = 4)
Figure 1  Patient flowchart .
  Final diagnosis Benign FNA Non-diagnostic FNA
  Confirmed benign on follow up    321   51
  Confirmed malignant on follow up      42   0
  Total of patients with follow up   36   5
Table 6  Final diagnosis for patients with non-malignant biop-
sies for who follow up was available
1Follow up CT; 2Subsequent CT-guided adrenal biopsy (n = 2), enlarge-
ment on repeat CT (n = 1) or adrenalectomy (n = 1). FNA: Fine-needle 
aspiration; CT: Computed tomography.
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cedure. Nevertheless, a careful review of  the available 
records was performed and all patients were contacted 
for short term events within 48 h of  the procedure. 
Secondly, many patients with benign adrenal gland FNA 
cytology had underlying cancer and died before follow-
up CT or never followed up, which could have affected 
the final diagnosis of  the nature of  the adrenal gland ab-
normality. However, because follow-up imaging was not 
available for these patients, they were excluded from the 
sensitivity analysis. 
Another potential limitation is that during several 
years of  the study time period, PET scan was not avail-
able and therefore is not applicable to this case series. 
With the advent of  PET, any decision to pursue a biopsy 
for a positive or indeterminate PET scan is generally 
at the discretion of  the referring physician. With wide-
spread metastatic disease, a positive scan within either 
adrenal is likely considered as diagnostic for metastatic 
disease and therefore a biopsy would not be necessary. 
However, in a patient with known or suspected malig-
nancy and a positive adrenal gland on PET in isolation, 
we advocate EUS-FNA of  the adrenal as this may sig-
nify novel metastatic disease which may merit additional 
or novel chemotherapy or possibly adrenalectomy.
In conclusion, EUS-FNA of  the adrenal is a safe, 
minimally invasive and sensitive technique with signifi-
cant impact in the management of  patients with malig-
nancy diagnosed either prior or during the procedure. 
It permits surgical treatment for cancer in patients with 
localized malignancy and a benign adrenal lesion. This 
technique also diagnoses metastatic disease and cancer 
recurrence, avoiding unnecessary invasive surgical pro-
cedures in patients with established metastatic disease by 
adrenal biopsy.
COMMENTS
Background
Different modalities can be used to sample the adrenal glands. Image guided 
fine-needle aspiration using either CT and ultrasound guidance have traditionally 
been used. With the advent of new endoscopic techniques, endoscopic ultra-
sound guidance for fine-needle aspiration (EUS-FNA) of either adrenal gland 
has become a very plausible technique for this matter. There have been reports 
of adrenal gland EUS-FNA and this has shown to be a very safe and minimally 
invasive procedure.  
Research frontiers
When sampling adrenal gland lesions, especially in patients with known or sus-
pected underlying malignancy, it is of supreme importance not only the technique 
used possesses a great deal of diagnostic accuracy, but also to understand how 
did previous studies obtain that diagnostic accuracy; this relates to the method 
for follow up of lesions with benign cytology results. This is a very important area 
of research in this subject.
Innovations and breakthroughs
Most publications regarding EUS-FNA have universally included patients with 
underlying malignancy and, have had small patient numbers and/or have not 
included repeat imaging to document follow up on lesions with benign cytology 
results. According to the recommendations of the American Association of Clini-
cal Endocrinologists and American Association of Endocrine Surgeons, adrenal 
lesions with benign appearance and smaller than 4cm, should have repeat 
adrenal imaging at 3-6 mo. These same guidelines also recommend surgery 
if the growth rate exceeds 1cm or if the lesion becomes hormonally active. In 
our study, we included 94 patients that had EUS-FNA of either adrenal gland, 
reviewed records and, abstracted information about EUS indication, EUS find-
ings, EUS-FNA results, clinical and follow up imaging if this was available. A true 
diagnosis of a benign lesion was considered when there was a benign EUS-
FNA result and the lesion had not grown more than 1 cm from its original size on 
follow up CT/MRI or repeat EUS or if the patient underwent adrenalectomy when 
the surgical pathology was benign. The clinical impact of adrenal EUS-FNA was 
analyzed on a case by cases basis. In the present study, the authors showed 
that adrenal gland EUS-FNA is a sensitive, specific, and safe minimally invasive 
diagnostic technique that has a great impact in patient care. Adrenal gland 
EUS-FNA ruled out metastatic disease in patients with underlying malignancy, 
therefore permitting surgery for primary tumor; it also made the initial diagnosis 
of stage Ⅳ cancer or recurrent malignancy in others. 
Applications
This study suggests that adrenal gland EUS-FNA is a clinically useful, accurate 
and a safe technique in patients with adrenal gland mass or enlargement regard-
less or the presence of underlying malignancy. 
Terminology
Endoscopic ultrasound (EUS) or echo-endoscopy is a procedure in which en-
doscopy is combined with ultrasound to obtain images of the internal anatomy. 
Combined with Doppler imaging, nearby blood vessels can be evaluated. During 
the performance of this procedure, abnormal structures can be biopsied using a 
fine-needle aspiration technique. 
Peer review
This is a retrospective single-center case-series evaluating the impact of EUS-
FNA (Endoscopic ultrasound guided fine-needle aspiration) in the evaluation of 
patients with left and/or right adrenal gland lesions discovered at EUS as part of 
a staging procedure or incidentally for other indications. The authors should be 
congratulated in their effort to present real clinical impact of EUS-FNA in patients 
with both malignant and benign adrenal lesions/findings that has never been 
done before, where patient population were mainly patients with cancer who 
were undergoing EUS-FNA for staging purposes.  
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